Efficacy and Safety of Bivalirudin Plus Half/Full Dose of Tirofiban in Patients Undergoing Emergency Percutaneous Coronary Intervention

摘要

Background and Objective: A combination of bivalirudin and tirofiban is commonly applied in percutaneous coronary intervention (PCI). This study was conducted to evaluate the safety and efficacy of bivalirudin plus half/full dose of tirofiban in perioperative treatment of PCI. Methodology: The patients with acute coronary syndrome (ACS) undergoing PCI between January, 2013 and December, 2016 were investigated. Five hundred and twenty-five patients were divided into bivalirudin+a half dose of tirofiban group (half dose group) and bivalirudin+a full dose of tirofiban group (full dose group). The efficacy index was evaluated by thrombolysis in myocardial infarction (TIMI) flow grade, the cardiac function, major adverse cardiovascular events (MACE). The safety index was evaluated by bleeding events after PCI. Data were analyzed by SPSS software. Continuous variables were statistically analyzed by Student?s t-test. Categorical variables were assessed by chi-square analysis. Results: The improvements of TIMI flow, cardiac function and the decreased incidence rates of MACE were shown no significant differences between the two groups. The occurrences of bleeding events in 4, 48 and 96 h, 30 and 90 days in half dose group were obviously lower than full dose group after PCI (pConclusion: This study revealed that half dose of tirofiban based treatment has the similar therapeutic effect and higher safety compared with full dose of tirofiban based treatment in patients with ACS undergoing emergency PCI.